Why the study?
To update the atrial fibrillation clinical performance and quality measures for public reporting, pay-for-performance programs, and quality improvement based on the 2019 guideline update.
The 2020 ACC/AHA update provides revised clinical performance and quality measures for adults with atrial fibrillation, aligning with the 2019 guideline updates on valvular AF and CHA2DS2-VASc thresholds.
Prompts adoption of updated AF performance measures in practice; extends 2019 guideline into quality metrics for reporting and research.
This document describes updates to the atrial fibrillation performance measures that are appropriate for public reporting or pay-for-performance programs. 2. The performance measures are taken from the 2019 American College of Cardiology/American Heart Association/Heart Rhythm Society atrial fibrillation guideline update and are selected from the strongest recommendations (Class 1 or 3). 3. Quality measures are provided that are not yet ready for public reporting or pay-for-performance programs but might be useful for clinicians and healthcare organizations for quality improvement. 4. The recent guideline change regarding the definition of valvular atrial fibrillation is now incorporated into the performance measures. This includes patients with moderate or severe mitral stenosis and those with a mechanical prosthetic heart valve. 5. The recent guideline changes regarding different CHA 2 DS 2 -VASc risk score treatment thresholds for men (>1) and women (>2) are now incorporated into the performance measures.
No takes yet. Share an insight, caveat, or question.
Heidenreich et al. (2020) conducted a review in Atrial Fibrillation or Atrial Flutter. The 2020 ACC/AHA update provides revised clinical performance measures for atrial fibrillation, incorporating new definitions for valvular AF and sex-specific CHA2DS2-VASc treatment thresholds.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: